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1Economic Impacts of Banning Subtherapeutic Use of
Antibiotics in Swine Production
Public health officials and physicians are concerned about possible development of
bacterial resistance and potential effects on human health that may be related to the use of
antimicrobial agents in livestock feed. The focus of this research is aimed at determining
the economic effects that subtherapeutic bans of antimicrobilas would have on both swine
producers and consumers. The results show that a ban on growth promotants for swine
would be costly, totaling $242.5 million annually with swine producers sharing the larger
portion in the short run and consumers sharing about 75% in the long run. If a ban
affected poultry as well as pork production, the total costs would expand to $586 million
per year with swine producers sharing about the same as in bans for swine only and
consumers sharing significantly more than the swine only case.
Key words: banning subtherapeutic use, feed efficiency, mortality rate, sort loss at
marketing.
Food animal production in the United States uses antimicrobial agents to promote animal
welfare and to enhance the efficiency of livestock production. Of the total antibiotic
production for both human treatment and animal purposes, approximately 25% is used in
food animals and 90% of that portion has been reported as being used in subtherapeutic
concentrations for disease control and as growth promotants.
Antimicrobial agents have been added to feed and used extensively in swine
production since their introduction in the early 1950s (Radostits). Swine performance is
potentially improved by using subtherapeutic concentrations of any of the 12 currently
available antibiotic or chemotherapeutic drugs that are approved for use in hogs with
claims for increased rate of gain or improved feed conversion (FDA). Because of the
economic benefit to producers, antimicrobial drugs are used in about 90% of the starter
feeds, 75% of the grower feeds, and over 50% of the finisher feeds (Cromwell).
Growth promotant or subtherapeutic use of antimicrobials administered in animal
feeds has been strongly criticized as a serious public health threat causing life-threatening
2infections that are resistant to antimicrobial therapy (Angulo; Witte). This concern has
developed around the following issues: (1) subtherapeutic use of antimicrobials in animal
feeds creates antimicrobial-resistant bacteria; (2) if subtherapeutic use were eliminated,
the level of resistance of bacteria harbored by animals would be reduced; and (3) reduced
resistance to antibiotics in animals would improve human health because the potential for
transmitting antibiotic-resistant bacteria from animals to humans would be reduced
(National Research Council 1998). However, in spite of these claims, which have been
considered more speculation than fact, there appears to be no clear-cut, definitive answer
regarding whether subtherapeutic use causes resistance and adverse effects on human
health. Nonetheless, it appears that human health officials are moving towards the
withdrawal of antimicrobials that are used for growth promotants in animals if these
drugs are also used for human therapeutics (Herrick).
The Animal Health Institute has estimated that growth promotants save hog
producers an estimated two billion dollars in annual production costs. However, not all
swine producers rely on these compounds to the same extent. Responses to
subtherapeutic uses of antimicrobials tend to be more positive when pigs are raised under
less than ideal conditions. Therefore, it is likely that producers who have good
management practices would not be as greatly affected by a ban as producers with less
desirable management systems. It has been suggested that a ban on subtherapeutic drug
use could ultimately improve animal care and improve industry efficiency, but the
process to achieve that result could be painful for those producers who are unable to
adopt improved management practices and are forced out of business. The overall effect
of a ban on antimicrobial drugs used as growth promotants, including the need to adopt
3technological improvements to obtain equal levels of production, would likely be an
increase in costs and higher meat prices.
Earlier studies on the economic impacts of bans on antimicrobial use in swine
production were conducted in the 1970s and indicated an increase in the market price of
pork and a 4 to 20% reduction in the quantity of pork supplied to the market (Burbee;
Gilliam). Shifts in technology and changes in management systems would likely alter
these results that were obtained more than 20 years ago.
In two of the more recent economic studies dealing with the ban on subtherapeutic
antimicrobials in swine production, a basic assumption was made that would appear to
seriously flaw the results of these reports (Manchanda; Wade and Barkley). Both of these
studies assumed that there would be an increase in the demand for pork of 5% because of
perceived improvements by consumers that pork produced under these bans would be
more wholesome and less likely to contain antibiltic residues. This assumption seems to
be unfounded because further decrease in the extremely low level of current antibiotic
residue rates would be unlikely. Because of this assumption, the study by Wade and
Barkley reported net economic gains for both producers and consumers due to the
proposed ban on antibiotics.
The most recently published economic evaluation (National Research Council
1998) of the effects of a ban on subtherapeutic use of antimicrobials in swine production
also included some assumptions and methods that were questionable. This study assumed
that there would be no change in consumption with a concomitant increase in the market
price of meat. No elasticity measurements were included in this study that would make
adjustments for changes in consumer demand due to price increases and provide for
4economics changes related to substitution effects among competing goods, such as beef
or poultry.
The current climate of increased regulatory pressures by health officials and
notable deficiencies or flaws in previously reported studies on the economic impact of
restricted antimicrobial use policies indicate the need to obtain better quality information
about this potential economic problem facing the U.S. pork industry.
The objective of this study is to develop useful economic estimates of the impact of
potential restricted-use policies for antimicrobial agents used in swine production as
growth promotants. By using a model similar to that used by Wohlgenant, the economic
impacts of banning antimicrobials agents in swine production are measured by the
changes in producers and consumers surplus.
Estimation of the Surplus Changes from the Bans of Antimicrobials
A model used by Wohlgenant allows for feedback effects between the beef and pork
markets, and can be used to measure the changes in producers and consumers surplus
due to the shifts in both demand and supply curves. Our purpose is to measure the
changes in producers and consumers surplus in the three commodity markets due to the
bans of antimicrobials in swine production. We thus need to modify the model in two
dimensions: we extend the two commodity model to a three commodity model; we set the
parameters corresponding to the shifts in demand curves equal to zeros and only consider
the effects of the shifts in the supply curves due to the bans. Explicitly, our modified
model is
                                           Qj* = ηj1P1*  + ηj2P2* + ηj3P3*                                            (1a)
5                                                   Pj* = SjWj*                                                                    (1b)
                                                Xj* = -(1  Sj)σjWj* + Qj*                                                (1c)
                                                     Wj* = (1/εj)Xj* - kj                                                                                  (1d)
j = 1, 2, 3.
where asterisks denote approximate relative changes (i.e. X* = dX/X), subscript 1, 2, and
3 denote beef, pork, and poultry respectively, Q represents quantity of retail product, P is
retail price, X is quantity of farm product, W is farm price, ηji is the elasticity of demand
for the jth retail product with respect to price of the ith product, σj is the elasticity of
substitution between the farm product and marketing inputs in producing the jth product,
Sj is the farmers cost share of the jth retail product, εj is the elasticity of supply of the jth
farm product, and kj is the relative decrease in production cost for the jth farm product.
Once the parameters in (1) are given, the values of the variables with asterisks can
be determined by solving the equations simultaneously. Using the total farm revenue and
total consumer expenditures, changes in producers and consumers surplus can be
calculated as
                                          ∆PSj = WjXj(Wj* + kj)(1 + 0.5Xj*)                                        (2a)
                                                ∆CSj = -PjQjPj*(1 + 0.5Qj*)                                             (2b)
 j = 1, 2, 3
where ∆PS denotes the change in producers surplus, ∆CS denotes the change in
consumers surplus. The total farm revenue WjXj and total consumer expenditures PjQj
are predetermined.
All parameters necessary to apply the equations in (1) and (2), except the parameter
representing the change in production costs, will be from other researchers results
6(Wohlgenant, Brester and Schroeder). The production cost change parameter k is
determined by simulations illustrated as follows.
Production Cost Changes Due to Banning Use of Growth Promotants
The production cost changes due to banning use of growth promotants are measured
indirectly by the net benefits from using growth promotants. Three key components were
identified as the most important for contributing potential economic advantages for
growth promotant use at the producer level: a) improved feed efficiency over drug cost,
b) reduced mortality rate, and c) reduced sort loss at marketing. The net economic benefit
for growth promotants in swine production is the sum of these components. The per
animal net benefits are then used to calculate the net benefit at the industry level.
Economic Benefit from Improved Feed Efficiency Over Drug Cost
The stochastic relationship between the economic benefit per pig and the improvement in
feed to gain conversions (F/G) in swine production is modeled as
                           Economic Benefit = α + β(Improvement in F/G) + ε                            (3)
where α and β are the parameters to be estimated, ε is a random variable with zero mean.
Improvement in F/G is a random variable with a probability distribution to be
determined.
Scientific literature was reviewed to determine the probability distribution of the
improvement in F/G, and the parameters α and β. This literature search provides the data
shown in Table 1. Reports were restricted to feeding trials using antimicrobial
compounds that are presently available for use in swine; reports on those compounds
7under development or not yet approved for use by FDA in swine feed were excluded.
Data from feeding trials limited to extremely brief periods of the production cycle, such
as those associated with segregated early weaning programs, and from the report based
upon producer surveys instead of actual feeding trials were excluded from calculations.
Improvements in feed-to-gain ratio (F/G) for subtherapeutic levels of
antimicrobials were reported as ranging from 1% (a decrease) to 5% or greater for
grower/finisher hogs. The mean improvement in F/G was 2.74% with a standard
deviation of 1.88% based upon 16 different values in the literature from feeding trials
covering significant periods of the grower/finisher phase of swine production. These data
best fit a normal distribution compared to alternative distributions (see Figure 1). Thus
F/G is assumed to follow a normal distribution with 2.74 as the mean and 1.88 as the
standard deviation.
A linear regression is used to determine the parameters α and β. Economic values
derived from drug use during extremely brief periods of the production cycle or from
therapeutic dose rates were excluded from the regression analysis. The regression based
on the data in Table 1 shows the following estimated equation.
                            Economic Benefit = 
)14.0()42.0(
66.068.1 + (Improvement in F/G)                        (4)
                                            R2 = 0.85
This result is used to estimate the economic benefit per pig from the improvement in F/G.
Economic Benefit from Reduced Mortality Rate
Subtherapeutic use of antimicrobials affects mortality rates, especially on younger pigs,
although these effects are not well documented. Unpublished data from 67 experiments
8conducted on swine farms over a 23-year span indicated an overall improvement in
mortality rates of 2% for pigs receiving antibiotics as growth promotants (Zimmerman
1986). Only two of the published reports in Table 1 provided data about differences in
mortality rates associated with the use of antimicrobial agents. Walter, Holck, and Wolff
(1999) evaluated therapeutic levels of tiamulin and chlortetracycline fed from 11 weeks
of age for a period of 16 weeks to more than 1,000 modern crossbred lean genotype
barrows in a commercial swine production system. Treatments were divided among
continuous delivery of medication in feed, pulse delivery of medication for seven days
administered every two or three weeks, and a nonmedicated control group. Mortality
rates for pigs in these groups were 0.55, 1.92, and 5.22% respectively, with both
medication groups having significantly less mortality than controls. Gourley (1998)
evaluated low-level continuous and high-level pulse (one week out of four) medication
regiments for delivering chlortetracycline in feed to 576 grower/finisher pigs from a lean
genotype, high health swine herd. The third treatment was a nonmedicated control group.
The mortality rates for the three treatment groups were 2.60, 2.08, and 3.13%
respectively. Although there was an advantage for pigs receiving medication, none of
these mortality differences in this study was significantly different. In view of the fact
that, from the two published reports, the average mortality difference between the
treatments is 1.43%, we model the mortality benefit associated with growth promotants
as a symmetric triangular distribution with minimum 0, most likely 0.75, and maximum
1.5%.
The market price used for hogs is $45.00 per cwt. This price is based on an
approximate ten-year average market hog price (Walter 1999). Then market price of hogs
9is used indirectly to establish value of 40 lb feeder pigs needed to calculate benefits
associated with reduced mortality rates. Using current feeder pig pricing schedules as a
guideline (USDA Iowa Department of Agricultural Market News at
http://www.ams.usda.gov/mnreports/NW_LS255.txt), we also assume that heavier feeder
pigs are worth $0.45 per pound for additional weight over 40 pounds. Weights of pigs
associated with the risk of dying that could be reduced due to feeding growth promotants
is modeled as with minimum value 40, most likely value 60, and maximum value 80 lb
respectively.
Economic Benefit from Reduced Sort Loss at Marketing
When the weights of market hogs fall outside of the packer specified weight range,
pricing discounts are applied, especially for lighter hogs, based on price schedules or
grid pricing. The term sort loss has been used by the swine industry to describe the
dollar loss related to these market hogs, which receive price discounts. Growth
promotants improve the uniformity of average daily gain, and, therefore, reduce the
ending weight variability and associated sort loss for market hogs (Tillman 1996;
Gourley et al. 1997; Gourley 1998). The size of the sort loss benefit would vary
according to the type of feeding management. Production systems using targeted days on
feed would achieve potentially greater benefits related to reduced sort loss compared to
targeted marketing weight management systems because the time schedule for a targeted
days system would typically provide less opportunity for delayed marketing to allow
additional gain for lighter weight pigs. A report by Tillman (1996) provided data on
average ending weight and standard deviations for the effect of a growth promotant on
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reducing sort loss in market hogs compared to a control group based on a targeted days
on feed production system. The normal distribution function was used to determine
cumulative proportions within each group as inputs for calculating differences in
distributions between these two groups. Sort losses at slaughter were based on grid
pricing discounts announced by Farmland for underweight hogs (Table 2). These data
provide an overall mean value of $1.39 with standard deviation of $0.15 per hog benefit
for growth promotants in reducing sort loss for targeted days production systems. It is
assumed that this benefit would be only one-third as much, i.e. mean $0.46 with standard
deviation $0.05, for hogs produced under targeted weight production systems because of
increased opportunity to allow longer feeding periods to achieve desired market weights,
which would reduce the chance of price discounts. No benefits were included for any
reduction in days on feed associated with the use of growth promotants.
Estimating the Total Net Economic Benefits at Industry Level by Simulation
As outlined before, the total net economic benefits from using growth promotants are
from three random sources, i.e. normally distributed improvement in F/G, triangularly
distributed reduced mortality rate, and normally distributed reduced sort loss at
marketing. To estimate the total economic benefits, we need convert the scale from
producer level to industry level.
The number of market barrows and gilts slaughtered per year is extrapolated from
annual USDA livestock slaughter summary reports for years 1994-2000 (National
Agricultural Statistics Service, Agricultural Statistics Board, USDA). These summaries
report figures ranging from 86.5 to 96 million head for years 1996 and 1999 respectively.
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Based on these data, an annual production of 100 million market barrows and gilts is
assumed for the simulation.
The proportion of grower/finisher pigs receiving antimicrobials as growth
promotants and the proportion of grower/finisher pigs managed as all-in/all-out are based
on population estimates from the Swine 95 project (USDA, APHIS, VS, CEAH 1995)
(see Table 3). We project that 85% of grower/finisher pigs would receive growth
promotants in feed and that 55% of hogs would be raised in an all-in/all-out
grower/finisher system.
Once the probability distributions of three sources of economic benefits at industry
level are given, the total net economic benefits are estimated Monte Carlo simulations on
each of the three components and summarizing them together. The expected net benefit
could have been approximated with analytical methods by assuming normality. The
Monte Carlo method accommodates nonnormal distributions and provides a convenient
way of calculating the uncertainty of the estimate.
Results
Based on a 5,000 iteration simulation, the total estimated net benefit for subtherapeutic
use of antibiotics in swine production was calculated as $2.76 ± $0.56 per hog as
determined by the previously described components. Although a wide spread in the value
of this benefit was possible, the majority of values most likely to occur would range from
$2.37 to $3.11 per hog (Figure 2). The average benefit of $2.76 per hog was used to
calculate the proportional change in production costs for the swine industry and the
resulting impact on economic values related to changes in supply and demand of pork in
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the U.S., if the use of subtherapeutic antibiotics in feed were banned. If the resulting
change in cost of pork production is lower or higher than assumed, all numbers change
proportionately. The calculated average increased cost of production of $2.76 per hog due
to loss of the net benefits associated with growth promotants was considered to be the
best estimate for figuring the cost change listed in Table 4. The number of hogs marketed
per year is estimated as 100 million heads. All price elasticities in Table 4 are
Marshallian.
Given all parameters and data in Table 1, the variables with asterisks in equation
(1), i.e. the retail products, retail prices, farm products, and farm pries for the three
commodities, are obtained by solving the simultaneous equations (1). Substituting the
solution for (1) into (2), we obtained changes in producers and consumers surplus. By
setting specific parameters equal to zeros, the changes in producers and consumers
surplus obtained are the ones due to banning subtherapeutic antibiotics in swine only or
both swine and poultry production.
The total annual loss in short run would be $242.5 million (the sum of the first row
in Table 5) if the ban on antimicrobials as growth promotants were on pork alone and
$673 million (the sum of the second row in Table 5) if the ban were applied to pork and
poultry. Table 5 shows that in the short run, the estimated loss borne by swine producers
would $153.5 million if the ban were only on swine production and $149.6 million if the
ban is across pork and poultry. In the long run, the total losses will be similar, $242.4
million and $586 million respectively, but consumers would bear more of the cost. In the
long run the swine producer surplus lost will be $62.4 million if the ban is only on pork
and $59.7 million if the ban is across pork and poultry. Because of the low price elasticity
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between pork and poultry, it does not make much difference to swine producers as to
whether the ban included swine only or also included poultry.
Conclusion
A ban on the use of antimicrobial agents as growth promotants for swine would be costly,
totaling $242.5 million annually with swine producers bearing $153.5 of the cost in the
short run. In the long run, consumers would bear about 75% of the total cost. If a ban
affected poultry as well as pork production, the total losses would expand to about $586
million per year with larger portion of the cost bear shifted from the producers in the
short run to the consumers in the long run. Based on a 30-year planning horizon and a 4%
discount rate, the net present value of these increased costs would be $8.4 billion and
$11.6 billion, respectively, for a ban that would affect pork or both pork and poultry
production.
It should be noted that wide ranges of published elasticity estimates were available.
The elasticity estimates determined whether producers of consumers incurred the cost of
the ban. Because neither pork nor poultry production uses many resources that are
specialized and fixed in the long run, their supply curves are likely very elastic in the
long run.
The estimates of the total cost of banning subtherapeutic antimicarobial use in
swine and poultry were roughly half of that estimated by Committee on Drug Use in
Food Animals (National Research Council 1998). The main difference was that they
assumed that marketing cost would increase proportionately to any change in production
cost while this model held marketing costs constant.
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Table 3.  Management of Swine Farms Related to Growth Promotant Use in
Grower/Finisher Pigs and Prevalence of All-in/All-out Production System.
Swine 95 report
Mean s.e.
Growth Promotant Use
Percent of swine operations 91.3 2.0
Percent of grower/finisher hogs on those
operations 92.7 1.5
Percent of pigs receiving growth
promotants 84.6
Input used for simulation model 85.0 2.0
Grower/Finisher Management
Percent hogs, all-in/all-out production
system 51.0 2.2
Sources: U.S. Animal and Plant Health Inspection Service, Veterinary Services, Centers
for Epidemiology and Animal Health.  Swine 95.  Part 2: Reference of 1995 U.S.
grower/finisher health & management practices and Part 3: Changes in the U.S. pork
industry, 1990-1995.  Fort Collins, CO: Centers for Epidemiology and Animal Health,
USDA, 1995.
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Table 4.  Estimates of Parameter Values for the U.S. Beef, Pork and Poultry Industries
Value
Beef Pork Poultry
Price elasticity of demand for beef (η1) -.6 .1 .21
Price elasticity of demand for pork (η2) .14 -.35 .04
Price elasticity of demand for poultry (η3) .05 .07 -.3
Elasticity of substitution (σ) .72 .35 .35
Elasticity of farm supply, short run (εSR) .15 .2 .2
Elasticity of farm supply, long run (εLR) .70 1 1
Farmers share of consumers dollar (S) .49 .4 .4
Increase in production costsa (k) 0 .02023 0b
Total farm revenue (WX) $35 bil. $12 bil. $17 bil.
a The proportional change in production costs was calculated as:
• increased production cost per hog due to growth promotant ban = $2.76
• $2.76*84.6% utilization of growth promotants = $2.33 per hog for industry
• weight of one pig = 256 lb. = 2.56 cwt
• market value per pig = $45/cwt*2.56 = $115.20
• production cost increase  =  $2.33/$115.20 = 2.023%
b When a ban is assumed to affect both pork and poultry, the increase in production costs
is .02023.
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Table 5.  Change in Producer and Consumer Surplus from Increase in Production Costs
Due to Banning Subtherapeutic Antibiotics in Swine Only or Both Swine and Poultry
Production ($ Million)
Producers Consumers
Situation    Beef  Pork   Poultry  Beef   Pork Poultry
Ban, short run
Pork only 14.3 -153.5 7.0 -14.3 -89.0 -7.0
Pork & poultrya 42.7 -149.6 -206.0 -42.7 -92.9 -137.6
Ban, long run
Pork only 16.1 -62.4 5.5 -16.1 -180.0 -5.5
Pork & poultrya 49.3 -59.7 -79.3 -49.3 -182.7 -264.3
a The same percentage increase in cost for pork was assumed for poultry.  No change in
cost of beef production was assumed.
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